The Landscape of Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Healthcare professionals who care for patients with genitourinary, gastrointestinal, and gynecologic malignancies can gain insights into the most up-to-date advances in and clinical evidence of HER2-targeted antibody–drug conjugates in these cancer types and a better understanding of HER2 alterations and oncogenic mechanisms through certified podcasts and Medical Minutes as well as an expert-written ClinicalThought commentary and downloadable slides.

Share

Program Content

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.